专利快速检索-快速检索全球专利，免费商用专利数据库-IPRDB

1. 发明申请

US20090214587A1 Recombinant virus and use thereof 审中-公开
标题翻译：重组病毒及其用途
公开(公告)号：US20090214587A1
公开(公告)日：2009-08-27
申请号：US11576829
申请日：2005-10-11
申请人： Michinori Kohara , Kyosuke Mizuno , Hisatoshi Shida , Kouji Matsushima , Koichi Morita , Minoru Kidokoro , Yukie Sameshima
发明人： Michinori Kohara , Kyosuke Mizuno , Hisatoshi Shida , Kouji Matsushima , Koichi Morita , Minoru Kidokoro , Yukie Sameshima
IPC分类号： A61K39/215 , C12N7/00
CPC分类号： C12N15/86 , A61K39/12 , A61K39/215 , A61K2039/5256 , C07K14/005 , C12N7/00 , C12N2710/24143 , C12N2770/20022 , C12N2770/20034 , C12N2830/15
摘要： The present invention provides a recombinant virus which is efficacious and highly safe in preventing the onset of SARS infection and a vaccine for SARS coronavirus containing the same. The recombinant virus of the invention can express a SARS coronavirus gene.
摘要翻译：本发明提供一种在预防SARS感染发作中有效和高度安全的重组病毒，以及含有该SARS冠状病毒的疫苗。本发明的重组病毒可以表达SARS冠状病毒基因。

2. 发明授权

US5662906A Non-a non-b hepatitis-specific antigen and its use in hepatitis diagnosis 失效
标题翻译：非乙型肝炎特异性抗原及其在肝炎诊断中的应用
公开(公告)号：US5662906A
公开(公告)日：1997-09-02
申请号：US449093
申请日：1995-05-24
申请人： Noboru Maki , Kenjiro Yamaguchi , Ayumi Toyoshima , Michinori Kohara
发明人： Noboru Maki , Kenjiro Yamaguchi , Ayumi Toyoshima , Michinori Kohara
IPC分类号： C07K14/18 , C12N15/40 , A61K39/29
CPC分类号： C07K14/005 , C12N2770/24222
摘要： This invention relates to a DNA fragment comprising a base sequence encoding a non-A non-B hepatitis-specific antigen polypeptide, said base sequence being obtained using genetic engineering techniques from non-A non-B hepatitis virus RNA which is isolated directly from blood plasma from non-A non-B hepatitis patients, to an expression vector and a transformant for use in the expression of the DNA fragment, to a single strand DNA sequence for PCR primer, and to use of said polypeptide and said single strand DNA sequence in the detection of the non-A non-B hepatitis virus. The recombinant polypeptide and the single strand DNA sequence for PCR primer make it possible to detect the non-A non-B hepatitis virus with extremely high accuracy.
摘要翻译：本发明涉及包含编码非A非乙型肝炎特异性抗原多肽的碱基序列的DNA片段，所述碱基序列使用从直接从血液中分离的非A非乙型肝炎病毒RNA的遗传工程技术获得来自非A非B型肝炎患者的血浆，用于表达DNA片段的表达载体和转化体，用于PCR引物的单链DNA序列，以及使用所述多肽和所述单链DNA序列在非A非乙型肝炎病毒的检测中。用于PCR引物的重组多肽和单链DNA序列使得可以以非常高的精度检测非A非B型肝炎病毒。

3. 发明申请

US20110281271A1 Oligoribonucleotide or Peptide Nucleic Acid Capable of Inhibiting Activity of Hepatitis C Virus 有权
标题翻译：能够抑制丙型肝炎病毒活性的寡核苷酸或肽核酸
公开(公告)号：US20110281271A1
公开(公告)日：2011-11-17
申请号：US13130673
申请日：2009-11-26
申请人： Michinori Kohara , Masayuki Sudo
发明人： Michinori Kohara , Masayuki Sudo
IPC分类号： C12Q1/68 , C07H21/02 , C07H21/04 , C12N5/071
CPC分类号： C12N15/113 , C12N15/111 , C12N15/1131 , C12N2310/14 , C12N2320/11
摘要： The present inventors focused on siE sequences that have been thought to show RNAi activity against HCV viral RNAs, and mainly selected the D5-50 and D5-197 regions present within the IRES region, and carried on the analysis. As a result, the present inventors successfully identified siRNA sequences that exhibit a more effective RNAi activity against hepatitis C virus RNAs. Furthermore, the siRNAs were demonstrated to have a significant inhibitory effect on HCV propagation in an in vivo system.
摘要翻译：本发明人着重于已被认为显示针对HCV病毒RNA的RNAi活性的siE序列，主要选择存在于IRES区域内的D5-50和D5-197区域，并进行分析。结果，本发明人成功地鉴定了对丙型肝炎病毒RNA表现出更有效的RNAi活性的siRNA序列。此外，证实siRNA在体内系统中对HCV繁殖具有显着的抑制作用。

4. 发明申请

US20060128617A1 Oligoribonucleotide or peptidic nucleic acid inhibiting function of hepatitis c virus 审中-公开
标题翻译：丙型肝炎病毒的寡核苷酸或肽核酸抑制功能
公开(公告)号：US20060128617A1
公开(公告)日：2006-06-15
申请号：US10543078
申请日：2004-01-23
申请人： Michinori Kohara , Tsunamasa Watanabe , Kazunari Taira , Makoto Miyagishi , Masayuki Sudo
发明人： Michinori Kohara , Tsunamasa Watanabe , Kazunari Taira , Makoto Miyagishi , Masayuki Sudo
IPC分类号： A61K38/16 , A61K48/00 , C07H21/02 , C12Q1/70 , C12N15/86 , C07K14/18
CPC分类号： C12N15/1131 , A61K31/7105 , A61K38/00 , C12N2310/3181
摘要： A method of inhibiting the replication ability of a hepatitis C virus (HCV) is provided. An oligoribonucleotide or a peptide nucleic acid which sequence-specifically binds to the HCV-RNA, and a therapeutic agent for hepatitis C which contains any of these components as an active ingredient are provided.
摘要翻译：提供了抑制丙型肝炎病毒（HCV）的复制能力的方法。提供了序列特异性结合HCV-RNA的寡核糖核苷酸或肽核酸，以及含有任何这些成分作为活性成分的丙型肝炎治疗剂。

5. 发明申请

US20120204279A1 POLYNUCLEOTIDE DERIVED FROM NOVEL HEPATITIS C VIRUS STRAIN AND USE THEREOF 失效
标题翻译：从新型丙型肝炎病毒株衍生的多核苷酸及其用途
公开(公告)号：US20120204279A1
公开(公告)日：2012-08-09
申请号：US13388382
申请日：2010-08-25
申请人： Michinori Kohara , Masaaki Arai , Chise Mukaidani
发明人： Michinori Kohara , Masaaki Arai , Chise Mukaidani
IPC分类号： A01K67/027 , C12Q1/68 , C12Q1/70 , C12N15/51 , C12N7/01 , C12N5/10 , G01N33/571
CPC分类号： C12Q1/707 , C12N7/00 , C12N2770/24221 , C12N2770/24222 , C12N2770/24243 , C12N2770/24251 , G01N2333/18 , G01N2500/10
摘要： A polynucleotide encoding the amino acid shown in SEQ ID NO:2 or SEQ ID NO: 5, or encoding an amino acid sequence having not less than 98% identity thereto; preferably a polynucleotide comprising replacement of the amino acid corresponding to glutamic acid at position 1202 of SEQ ID NO:2 (position 177 of SEQ ID NO:5) with glycine, replacement of the amino acid corresponding to glutamic acid at position 1056 (position 31 of SEQ ID NO:5) with valine, and replacement of the amino acid corresponding to alanine at position 2199 (position 1174 of SEQ ID NO:5) with threonine.
摘要翻译：编码SEQ ID NO：2或SEQ ID NO：5所示氨基酸的多核苷酸，或编码与其不同于98％同一性的氨基酸序列; 优选包括将SEQ ID NO：2（SEQ ID NO：5的第177位）的1202位相应于谷氨酸的氨基酸与甘氨酸取代的多核苷酸，替换对应于1056位谷氨酸的氨基酸（位置31 SEQ ID NO：5）与缬氨酸的氨基酸取代，并且用苏氨酸置换对应于位置2199（SEQ ID NO：5的位置1174）的丙氨酸。

6. 发明申请

US20100152433A1 ANTIVIRAL AGENT 审中-公开
标题翻译：抗病毒剂
公开(公告)号：US20100152433A1
公开(公告)日：2010-06-17
申请号：US12531735
申请日：2008-03-18
申请人： Michinori Kohara , Shin-ichiro Nakagawa
发明人： Michinori Kohara , Shin-ichiro Nakagawa
IPC分类号： C07H19/20
CPC分类号： A61K31/7088 , A61K9/1272 , A61K9/19 , A61K31/7115
摘要： The main purpose of the present invention is to provide a novel antiviral agent having a useful pharmacological action. The present inventors found that the above-described purpose can be achieved by a complex in which two synthetic RNAs (e.g., poly-I and poly-C) that can together form a double strand are contained in a drug carrier useful for transporting a drug into a cell (e.g., cationic liposome and atelocollagen), and thus the present invention was achieved.
摘要翻译：本发明的主要目的是提供一种具有有用药理作用的新型抗病毒剂。本发明人发现上述目的可以通过一种复合物来实现，其中可以共同形成双链的两个合成RNA（例如，聚-I和多聚C）包含在用于运输药物的药物载体中进入细胞（例如阳离子脂质体和小胶原蛋白），从而达到本发明。

7. 发明申请

US20060174354A1 Hcv gene transgenic animal 审中-公开
标题翻译： Hcv基因转基因动物
公开(公告)号：US20060174354A1
公开(公告)日：2006-08-03
申请号：US10494177
申请日：2002-09-24
申请人： Michinori Kohara , Hiroshi Suzuki , Otoya Ueda , Kou-ichi Jishage , Asao Katsume
发明人： Michinori Kohara , Hiroshi Suzuki , Otoya Ueda , Kou-ichi Jishage , Asao Katsume
IPC分类号： A01K67/027
CPC分类号： C12N15/8509 , A01K67/0275 , A01K2217/05 , A01K2227/105 , A01K2267/0337 , C07K14/005 , C12N2770/24222 , C12N2800/30
摘要： The present invention provides a transgenic animal expressing the full-length human hepatitis C virus (HCV) for the purpose of constructing a system for screening for a remedy for human hepatitis C. The present invention is a transgenic hepatitis C model animal, which has the full-length DNA of the hepatitis C virus incorporated therein and can express the full-length HCV gene, and a method of generating a hepatitis C model animal carrying the full-length HCV gene, which comprises introducing a vector containing the full-length DNA of hepatitis C virus into an ES cell, and causing the ES cells to undergo ontogenesis in a pseudo-parent.
摘要翻译：本发明提供了表达全长人丙型肝炎病毒（HCV）的转基因动物，目的是构建用于筛选人丙型肝炎的药物的系统。本发明是转基因丙型肝炎模型动物，其具有其中并入丙型肝炎病毒的全长DNA并能表达全长HCV基因，以及产生携带全长HCV基因的丙型肝炎模型动物的方法，其包括引入含有全长DNA的载体的丙型肝炎病毒进入ES细胞，并使得ES细胞在假亲本中经历发生。

8. 发明授权

US08466273B2 Hepatitis C virus inhibitors 有权
标题翻译：丙型肝炎病毒抑制剂
公开(公告)号：US08466273B2
公开(公告)日：2013-06-18
申请号：US12241868
申请日：2008-09-30
申请人： Kyoko Kohara , Michinori Kohara , Tomohiro Nishimura , Masaaki Sato
发明人： Kyoko Kohara , Michinori Kohara , Tomohiro Nishimura , Masaaki Sato
IPC分类号： C07H21/04
CPC分类号： C07K16/286 , C07K16/40 , C07K2317/73 , C07K2317/76
摘要： The present invention aims to provide hepatitis C virus inhibitors capable of inhibiting viral replication in hepatitis C virus-infected cells.The replication of hepatitis C virus can be inhibited and hepatitis C virus-infected cells can be specifically injured by specifically inhibiting BGT-1 or AKR1C1 involved in the replication of hepatitis C virus. Thus, viral inhibitors comprising a substance inhibiting BGT-1 or AKR1C1 are effective for the treatment of hepatitis C.
摘要翻译：本发明旨在提供能够抑制丙型肝炎病毒感染细胞中病毒复制的丙型肝炎病毒抑制剂。可以抑制丙型肝炎病毒的复制，通过特异性抑制丙型肝炎病毒复制中的BGT-1或AKR1C1可以特异性地损伤丙型肝炎病毒感染的细胞。因此，包含抑制BGT-1或AKR1C1的物质的病毒抑制剂对于治疗丙型肝炎是有效的。

9. 发明申请

US20110275139A1 RECOMBINANT VACCINIA VIRUS HAVING HEPATITIS C VIRUS GENE 有权
标题翻译：具有HEPATITIS C病毒基因的重组疫苗病毒
公开(公告)号：US20110275139A1
公开(公告)日：2011-11-10
申请号：US12736079
申请日：2009-03-06
申请人： Michinori Kohara , Fukashi Murai
发明人： Michinori Kohara , Fukashi Murai
IPC分类号： C12N7/01
CPC分类号： C12N15/8636 , A01K67/0275 , A01K2217/15 , A01K2217/203 , A01K2267/0337 , A61K35/13 , A61K39/12 , A61K39/29 , A61K2039/525 , A61K2039/5256 , A61K2039/57 , C07K14/005 , C12N15/8509 , C12N2710/24143 , C12N2770/24222 , C12N2770/24234
摘要： Provided is a recombinant virus which is efficacious in preventing the onset of hepatitis C infection and has a high safety. Also provided is a vaccine for hepatitis C virus which contains the recombinant virus. A recombinant vaccinia virus which can express hepatitis C virus gene. The hepatitis C virus vaccine as described above contains the recombinant virus as described above.
摘要翻译：提供一种重组病毒，其有效预防丙型肝炎感染的发生并具有高安全性。还提供了含有重组病毒的丙型肝炎病毒疫苗。可以表达丙型肝炎病毒基因的重组痘苗病毒。如上所述的丙型肝炎病毒疫苗含有如上所述的重组病毒。

10. 发明申请

US20090148424A1 Reversibly immortalized mammalian liver cells and use thereof 审中-公开
标题翻译：可逆永生化的哺乳动物肝细胞及其用途
公开(公告)号：US20090148424A1
公开(公告)日：2009-06-11
申请号：US10594544
申请日：2004-03-31
申请人： Naoya Kobayashi , Noriaki Tanaka , Michinori Kohara
发明人： Naoya Kobayashi , Noriaki Tanaka , Michinori Kohara
IPC分类号： A61K35/12 , C12N5/06 , C12N5/08 , A01N1/02 , C12N15/00
CPC分类号： C12N5/067 , A01K2207/15 , A01K2227/106 , A01K2267/035 , A61K35/12 , A61M1/3689 , C12N2510/04 , C12N2800/30
摘要： The present invention provides a reversibly immortalized mammalian liver cell line, especially CYNK-1 (deposited with International Patent Organism Depository, National Institute of Advanced Industrial Science and Technology, address: AIST Tsukuba Central 6, 1-1, Higashi 1-Chome, Tsukuba-shi, Ibaraki-ken, 305-8566 Japan, deposited date: Mar. 10, 2004, accession number: FERM BP-08657) comprising an immortalizing gene interposed between a pair of site-specific recombination sequences and a suicide gene in the outside of the pair of site-specific recombination sequences, characterized in that the suicide gene can exhibit its function after excision of the pair of site-specific recombination sequences, or passage cell line thereof; a mammalian liver cell obtained by excising the immortalizing gene from the reversibly immortalized mammalian liver cell line or passage cell line thereof; and use of these cells. By utilizing the reversibly immortalized mammalian liver cell line of the present invention enables the obtainment of the number of the liver cells and utilization as materials for artificial liver reactors and cell preparations.
摘要翻译：本发明提供了可逆地永生化的哺乳动物肝细胞系，特别是CYNK-1（保藏在国际专利生物保藏中心，国立先进工业科学和技术研究所，地址：筑波中心6-1-1，Higashi 1-Chome，Tsukuba -shi，Ibaraki-ken，305-8566日本，保藏日期：2004年3月10日，登录号：FERM BP-08657），其包含插入一对位点特异性重组序列之间的永生化基因和外部的自杀基因的特异性重组序列，其特征在于，自杀基因可以在切除一对位点特异性重组序列或其通过细胞系后显示其功能; 通过从可逆永生化的哺乳动物肝细胞系或其通过细胞系切除永生化基因获得的哺乳动物肝细胞; 并使用这些细胞。通过利用本发明的可逆永生化的哺乳动物肝细胞系，可以获得肝细胞的数量和用作人造肝反应器和细胞制剂的材料。

你已经成功收藏专利！

检索式保存成功!

IPRDB

热门服务

关于我们

友情链接

联系方式